The data, code, and detailed protocols are all available on github github.com/aiproteins/h... and all the plasmids are available on addgene www.addgene.org/233685/ www.addgene.org/233686/ www.addgene.org/kits/bahl-su...

GitHub - aiproteins/high_throughput_protein_production

Contribute to aiproteins/high_throughput_protein_production development by creating an account on GitHub.

github.com

Science is a team sport, and this project had an amazing team: Edson Cárcamo, Ian Truebridge, Frank Teets, James Bowman, Nathalia Rodriguez, and Tessa Howard

Every protein designer knows that producing & testing designed proteins is a foundational capability for our field, & this is still pretty challenging for a lot of folks. This is why I'm delighted to share our work to make high-throughput protein production more accessible dx.doi.org/10.1002/pro....

Facile, high‐throughput protein purification enabled by high‐efficiency protease elution

While advances in artificial intelligence have made protein design widely accessible, protein production and characterization remain a bottleneck. Protease-cleavable affinity tags are commonly used t....

dx.doi.org

Last week’s course was a big success, thanks to our guest speakers! Dane Wittrup @mitkochinstitute.bsky.social, Surge Biswas at Nabla Bio & Justin Peruzzi @aiproteins.com shared insights on yeast display, AI Ab design & miniprotein discovery. Sign up for future course updates ➡️ buff.ly/tTcDWZk

Three weeks ago, we welcomed the local scientific community to join us at our headquarters in Kenmore Square for the inaugural lecture in the AI Proteins Seminar Series. Our speaker Neil King from @uwproteindesign.bsky.social delivered a superb seminar. Check it out 👇 youtu.be/OPRMfRnlx1k

Neil King: ML-based design of nanoparticle vaccines (AI Proteins Seminar Series)

YouTube video by AI Proteins

youtu.be

⏰ Tomorrow! Join our webinar, Introduction to Protein Design for Africa, featuring speakers from AI Proteins, STEAMulater, Minimal Bio, and Nostrum Biodiscovery. Learn how protein design is advancing innovation and accessibility around the world! Register: us06web.zoom.us/webinar/regi...

Thank you to everyone who attended the inaugural lecture in the AI Proteins Seminar Series today. Neil King @kinglabipd.bsky.social gave a fantastic talk to a packed house!

We're delighted to kick off our new seminar series, and the inaugural speaker is none other than Neil King from the Institute for Protein Design, University of Washington "ML-based design of nanoparticle vaccines" June 3rd, 2026 12:00 PM – 1:00 PM EDT

Really fun and challenging (!) discussion with @cdbahl.com on BindCraft, the state of binder design, the oustanding challenges and perhaps also some misconceptions in the field 💫 www.healthtech.com/the-chain/ma...

Episode 84 Martin Pacesa on BindCraft An Automated Pipeline for De Novo Protein Binder Design

April 14, 2026 | How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at the University ...

healthtech.com

🚨 BIG News: PS40 will include an exclusive visit to AI Proteins HQ! 🎟️ RSVP opens mid-May (first come, first served) 💸 Free for attendees | 🚗 Travel not provided Learn more about AI Proteins from CEO Chris Bahl: “The secret language of cells—and how to ‘speak’ it” www.ted.com/talks/chris_...

The secret language of cells — and how to "speak" it

What if medicines could "speak" directly to your cells? Protein designer and TED Fellow Chris Bahl introduces a new generation of miniproteins: AI-designed medicines that can deliver detailed instructions to fix what's making you sick. He shares how this breakthrough could potentially unlock safer, more effective treatments for some of humanity's most challenging diseases.

ted.com

Our team is growing! We’re hiring for two new roles on our Biochemistry and Protein Characterization teams. These are hands-on, wet lab positions ideal for early-career scientists eager to make an impact and contribute to cutting-edge drug design. www.aiproteins.com/careers

We're recruiting a Research Associate to join our Bioprocess Development team. This is a wet lab role ideally suited for someone graduating college this spring who is excited to join a team pioneering a new therapeutic modality Check it out! 👇 www.aiproteins.com/open-positio...

I had a great time nerding out about protein design with @nickpolizzi.bsky.social, and an enormous thanks to @biotechtv.bsky.social and @massbio.bsky.social for hosting us! www.biotechtv.com/post/chris-b...

AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner

Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think ...

biotechtv.com

Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com! youtu.be/7O0s5AY46U0

Chris Bahl on the Conundrum of Biotech Platforms

YouTube video by Provolut

youtu.be

AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors. See the official press release for details: www.businesswire.com/news/home/20...

The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures. endpoints.news/boston-biote...

Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model

AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.

endpoints.news

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

My new @ted.com talk from the main stage just went live! go.ted.com/chrisbahl 🧵👇

The secret language of cells — and how to "speak" it

What if medicines could "speak" directly to your cells? Protein designer and TED Fellow Chris Bahl introduces a new generation of miniproteins: AI-designed medicines that can deliver detailed instruct...

go.ted.com

We're #hiring a Scientist in Mass Spectrometry! Apply today or share this post with your network: www.linkedin.com/jobs/view/42... (ignore what linkedin says - the search is still open) Interested? Please email your CV to: careers@aiproteins.bio

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer! www.businesswire.com/news/home/20...

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com! 🧵👇

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

It was an honor to speak from the main stage at TED last week about our work at AI Proteins Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

Welcome Phil Brandish, Chief Development Officer, to the AI Proteins team! www.businesswire.com/news/home/20...

AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer

AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of

businesswire.com

We're delighted to share that our #Founder Chris Bahl @cdbahl.bsky.social is now our CEO!

Chris Bahl@cdbahl.com · 2y ago

I’m excited to share that I am now the CEO of AI Proteins @aiproteins.bsky.social! I’m grateful to continue leading this exceptional team as we build upon the strong foundation that we’ve established since launching the company in 2021. www.businesswire.com/news/home/20... 🧵👇

So, I might have ended up on the jumbotron at the Celtics game proudly wearing my @aiproteins.bsky.social colors

Mireia Solà Colom, Head of Immunotherapeutics at AI Proteins, presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

Boston Protein Design and Modeling Club@bpdmc.org · 2y ago

for the folks who weren't able to join for the brilliant presentation by Mireia Solà Colom last week to cap off our 2024 seminar series, you can check out the recording 👇 youtu.be/e6oZgGWjD_0

Exciting times at @aiproteins.bsky.social ! We are getting so close to see our drugs helping patients! www.fiercebiotech.com/biotech/bris...

Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M

Bristol Myers Squibb has

fiercebiotech.com

AI Proteins is excited to partner with @bms-news.bsky.social to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes www.businesswire.com/news/home/20...

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

businesswire.com

We've got some very exciting news to share! businesswire.com/news/home/20... and here's a 🧵 about the journey from academia to @aiproteins.bsky.social

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

businesswire.com